Search Result

Results for "

choroidal neovascularization macular degeneration

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Drug Isomer (1) Interleukin Related (2) LPL Receptor (1) Small Interfering RNA (siRNA) (2) TNF Receptor (1) VEGFR (6)
By Research Areas:	Cancer (2) Cardiovascular Disease (4) Inflammation/Immunology (2) Neurological Disease (2)
Click Chemistry:	Azide (1)
Oligonucleotides:	siRNA drugs (2) siRNAs (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (K_d = 0.5 pM), VEGF-B (K_d = 8 pM), VEGF-C, and PlGF (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .

HY-153484A

Bevasiranib sodium	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-W1048555A

Mal-PEG2000-SCM	Biochemical Assay Reagents	Others
Mal-PEG2000-SCM is a heterobifunctional PEG crosslinker bearing maleimide and succinimidyl carboxymethyl ester functional groups. MMal-PEG2000-SCM conjugates the F3 peptide to nanoparticles: the SCM group reacts with amino groups on the nanoparticle surface to form amide groups, while the MAL group reacts with thiol groups of the F3 peptide to form carbon-sulfur bonds. Mal-PEG-SCM enables unidirectional addition of linkers, ensuring that appropriate functional groups are available for RGD incorporation. Mal-PEG2000-SCM can be used in the development of nanoparticles targeting specific tumor cells .

HY-15492

AG-13958 1 Publications Verification AG-013958	VEGFR	Cardiovascular Disease
AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .

HY-153484

Bevasiranib	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-184141

EYE1090	VEGFR	Neurological Disease
EYE1090 is an orally active VEGFR2 inhibitor with an IC₅₀of 3 nM. EYE1090 inhibits angiogenesis, endothelial migration, VEGFR2-induced retinal leakage, and reduces choroidal neovascularization lesion size in mice. EYE1090 can be used for the research of age-related macular degeneration, diabetic retinopathy, choroidal neovascularization .

HY-P992151

Sphingomab LT1002	LPL Receptor Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonal antibody and also an inhibitor targeting S1P, with high affinity for S1P and a K_d value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration .

HY-15492A

AG-13958 (mono(hydrochloride)) AG-013958 monohydrochloride	VEGFR	Cardiovascular Disease
AG-13958 monohydrochloride, a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .

HY-113040B

(±)-(17S,18R)-Epoxyeicosatetraenoic acid (±)-17(S),18(R)-EETeTr	Drug Isomer	Others
(±)-(17S,18R)-Epoxyeicosatetraenoic acid ((±)-17 (S),18 (R)-EETeTr) is one of the constituent enantiomers of (±) 17 (18)-EpETE. (±) 17 (18)-EpETE is an active metabolite of the ω-3 fatty acid eicosapentaenoic acid, and also an agonist of sphingosine-1-phosphate receptor 1 (S1P1) .

Cat. No.	Product Name	Type

HY-W1048555A

Mal-PEG2000-SCM	Biochemical Assay Reagents
Mal-PEG2000-SCM is a heterobifunctional PEG crosslinker bearing maleimide and succinimidyl carboxymethyl ester functional groups. MMal-PEG2000-SCM conjugates the F3 peptide to nanoparticles: the SCM group reacts with amino groups on the nanoparticle surface to form amide groups, while the MAL group reacts with thiol groups of the F3 peptide to form carbon-sulfur bonds. Mal-PEG-SCM enables unidirectional addition of linkers, ensuring that appropriate functional groups are available for RGD incorporation. Mal-PEG2000-SCM can be used in the development of nanoparticles targeting specific tumor cells .

Mal-PEG2000-SCM

Biochemical Assay Reagents

Mal-PEG2000-SCM is a heterobifunctional PEG crosslinker bearing maleimide and succinimidyl carboxymethyl ester functional groups. MMal-PEG2000-SCM conjugates the F3 peptide to nanoparticles: the SCM group reacts with amino groups on the nanoparticle surface to form amide groups, while the MAL group reacts with thiol groups of the F3 peptide to form carbon-sulfur bonds. Mal-PEG-SCM enables unidirectional addition of linkers, ensuring that appropriate functional groups are available for RGD incorporation. Mal-PEG2000-SCM can be used in the development of nanoparticles targeting specific tumor cells .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (K_d = 0.5 pM), VEGF-B (K_d = 8 pM), VEGF-C, and PlGF (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .

HY-P992151

Sphingomab LT1002	LPL Receptor Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonal antibody and also an inhibitor targeting S1P, with high affinity for S1P and a K_d value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration .

Cat. No.	Product Name		Classification

HY-184141

EYE1090		Azide
EYE1090 is an orally active VEGFR2 inhibitor with an IC₅₀of 3 nM. EYE1090 inhibits angiogenesis, endothelial migration, VEGFR2-induced retinal leakage, and reduces choroidal neovascularization lesion size in mice. EYE1090 can be used for the research of age-related macular degeneration, diabetic retinopathy, choroidal neovascularization .

Cat. No.	Product Name		Classification

HY-153484A

Bevasiranib sodium		siRNAs siRNA drugs
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-153484

Bevasiranib		siRNAs siRNA drugs
Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.